Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a review
Tehreem Fatima(King Edward Medical University), Aymar Akilimali(Roslin Institute), Riyan Imtiaz Karamat(CMH Lahore Medical College and Institute of Dentistry), Anam Mirza(CMH Lahore Medical College and Institute of Dentistry), Faiza Fatima(Services Institute of Medical Sciences), Iqra Shahid, Bilal Ahmad(Shaikh Zayed Postgraduate Medical Institute)
Cited by 7
Related Papers
Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
|Annals of Medicine and Surgery|2024|87
Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
|Annals of Medicine and Surgery|2023|30
Self-medication and Anti-malarial Drug Resistance in the Democratic Republic of the Congo (DRC): A silent threat
|Tropical Medicine and Health|2022|29
Barriers Encountered Toward Pursuing a Neurosurgical Career: A Cross-Sectional Study Among Medical Students, Interns, and Junior Doctors in Africa
|World Neurosurgery|2022|26
The unmet need of organ transplantation in Africa
|International Journal of Surgery|2023|21